AbbVie (ABBV) Acquisitions (2012 - 2025)

AbbVie has disclosed Acquisitions across 10 years of filings, most recently posting $204.0 million for Q1 2025.

• In Q1 2025, Acquisitions fell 97.78% year-over-year to $204.0 million; the TTM figure through Dec 2025 stood at $204.0 million (down 98.83% YoY), while the FY2025 annual figure was $204.0 million, down 98.83% from the prior year.
• Acquisitions fell to $204.0 million in Q1 2025, from $8.3 billion in the prior quarter.
• Over the last five years, Acquisitions for ABBV reached as high as $9.2 billion in Q1 2024 and fell as low as $204.0 million in Q1 2025.
• The 3-year median for Acquisitions is $4.4 billion (2021), against an average of $4.6 billion.
• Annual changes were most pronounced in 2021 — Acquisitions surged 330.33% — and 2025, when it tumbled 97.78%.
• A 3-year view of Acquisitions shows it stood at $525.0 million in 2021, then surged by 1479.81% to $8.3 billion in 2024, then tumbled by 97.54% to $204.0 million in 2025.
• According to Business Quant data, Acquisitions over the past three periods registered $204.0 million, $8.3 billion, and $9.2 billion for Q1 2025, Q3 2024, and Q1 2024 respectively.